Sign inJoin waitlistJoin the waitlist

Tianhong Li

Hematology & Oncology · Regents of the Univ of Ca

Credentials: · ·

History

Montefiore Medical Center, Albert Einstein College or Medicine
Until 2003
Beth Israel Medical Center, Albert Einstein College of Medicine
1998–2000
Beth Israel Medical Center, Albert Einstein College of Medicine
1997–1998
Beijing University School of Medicine
1989

Research

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Review · Journal of the National Comprehensive Cancer Network · 2022 · 415 citations
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies
Review · Journal of Clinical Oncology · 2013 · First of 4 authors · Corresponding · 408 citations
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Review · Journal of Hematology & Oncology · 2016 · Last of 4 authors · Corresponding · 269 citations

YZ
Yuhua Zheng
52 papers
Andrew Ukleja
27 papers
AF
Anna Falabella
27 papers
DL
Daniella Loh
27 papers
Gary Wormser
27 papers
Kathy Rinnert
27 papers
MP
Marriann Pappagallo
27 papers
Roger Lefevre
27 papers
Vanessa Battista
27 papers
WM
Weijie Ma
27 papers · 12 as a resident
David Gandara
21 papers · 7 as a fellow
Primo Lara
15 papers

Grants

Targeting Integrins in Lung Cancer
Department of Veterans Affairs · I01
Contact PI · Va Northern California Health Care Sys
2021–2025
First in Human Phase I/II Clinical Trial of ONC-392: Preserving CTLA-4 Immune Tolerance Checkpoint for Safer and More Effective Cancer Immunotherapy
National Cancer Institute · R44
PI · $2M · oncoc4, Inc.
2020–2023

Clinical trials

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
Principal investigator · Recruiting · Phase 1
OncoC4, Inc.
2024–2027
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Principal investigator · Active not recruiting · Phase 3
OncoC4, Inc.
2023–2028
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Principal investigator · Suspended · Phase 1, Phase 2
University of California, Davis
2021–2034
CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study
Principal investigator · Terminated · Phase 1, Phase 2
Tianhong Li
2020–2022